Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2.
Tumor suppressor genes evolved as negative effectors of mitogen and nutrient signaling pathways, such that mutations in these genes can lead to pathological states of growth. Tuberous sclerosis (TSC) is a potentially devastating disease associated with mutations in two tumor suppressor genes, TSC1 and 2, that function as a complex to suppress signaling in the mTOR/S6K/4E-BP pathway. However, the inhibitory target of TSC1/2 and the mechanism by which it acts are unknown. Here we provide evidence that TSC1/2 is a GAP for the small GTPase Rheb and that insulin-mediated Rheb activation is PI3K dependent. Moreover, Rheb overexpression induces S6K1 phosphorylation and inhibits PKB phosphorylation, as do loss-of-function mutations in TSC1/2, but contrary to earlier reports Rheb has no effect on MAPK phosphorylation. Finally, coexpression of a human TSC2 cDNA harboring a disease-associated point mutation in the GAP domain, failed to stimulate Rheb GTPase activity or block Rheb activation of S6K1.
Pubmed ID: 12820960 RIS Download
Adaptor Proteins, Signal Transducing | Animals | COS Cells | Carrier Proteins | Cell Line | Cercopithecus aethiops | Genes, Tumor Suppressor | HeLa Cells | Humans | Insulin | Monomeric GTP-Binding Proteins | Neuropeptides | Phosphatidylinositol 3-Kinases | Phosphoproteins | Point Mutation | Protein Kinases | Protein Structure, Tertiary | Proteins | Repressor Proteins | Ribosomal Protein S6 Kinases | Signal Transduction | TOR Serine-Threonine Kinases | Tumor Cells, Cultured | Tumor Suppressor Proteins